Investment Considerations Cybin Inc. currently has three molecules in development with four sponsored clinical trials planned for 2022 and a preclinical pipeline of 50+ novel assets. The company’s management team is composed of leaders with experience in various aspects of the pharmaceutical and innovative therapeutics market and is further supported by external partnerships with world-class … Continue reading “Cybin Inc. (NYSE American: CYBN) (NEO: CYBN)”
Investment Considerations In July 2023, LSDI launched Twilight, a new sleep aid product. The company in July 2023 announced its acquisition of SANA-013 from Wesana Health; SANA-013 is being developed for the treatment of several mental health and central nervous system conditions. LSDI in May 2023 launched its new Mindful product line designed to enhance … Continue reading “Lucy Scientific Discovery Inc. (NASDAQ: LSDI)”
Investment Considerations Silo recently extended its option with the University of Maryland, Baltimore to explore arthritogenic joint-homing peptides and their use in arthritis-inflamed joints. In December 2021, the company announced the issuance of a patent relating to its University of Maryland, Baltimore licensed homing peptide for enhanced targeting of therapeutic agents to the central nervous … Continue reading “Silo Pharma Inc. (NASDAQ: SILO)”
Investment Considerations Mydecine’s portfolio includes a robust line of NCEs (New Chemical Entities) and medicines based on compounds found in psychedelics, including four lead clinical trial drug candidates. The company has an exclusive partnership with Applied Pharmaceutical Innovation providing access to world-class, end-to-end drug development infrastructure under one roof. Mydecine’s management team features highly experienced … Continue reading “Mydecine Innovations Group Inc. (CSE: MYCO) (AQSE: MYIG) (OTC: MYCOF)”
Investment Considerations Tryp Therapeutics is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications. The company is targeting diseases with few existing treatments options for patients that represents more than $12 billion in annual sales potential. Tryp is initiating multiple Phase 2a clinical trials … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)”
Investment Considerations BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. The company has research and development operations in North America and Europe and an operational focus in Germany. BioNxt’s operations are concentrated into three core divisions: infectious disease diagnostics, clinical development of transdermal … Continue reading “BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: 4XT)”
